Synopsis
Synopsis
0
API Suppliers
 
																							0
USDMF
 
																							0
CEP/COS
 
																							0
JDMF
 
																							0
EU WC
 
																							0
KDMF
 
																							0
NDC API
 
																							0
VMF
 
																							0
Listed Suppliers
 
																							0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
 
																							0
Canada
 
																							0
Australia
 
																							0
South Africa
 
																							0
Listed Dossiers
 
																							
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid 
NA
Annual Reports 
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


| Molecular Weight | 534.6 g/mol | 
|---|---|
| Molecular Formula | C20H22N8O6S2 | 
| XLogP3 | -3.7 | 
| Hydrogen Bond Donor Count | 5 | 
| Hydrogen Bond Acceptor Count | 12 | 
| Rotatable Bond Count | 5 | 
| Exact Mass | 534.11037280 g/mol | 
| Monoisotopic Mass | 534.11037280 g/mol | 
| Topological Polar Surface Area | 250 A^2 | 
| Heavy Atom Count | 36 | 
| Formal Charge | 0 | 
| Complexity | 1200 | 
| Isotope Atom Count | 0 | 
| Defined Atom Stereocenter Count | 3 | 
| Undefined Atom Stereocenter Count | 0 | 
| Defined Bond Stereocenter Count | 2 | 
| Undefined Bond Stereocenter Count | 0 | 
| Covalently Bonded Unit Count | 1 | 
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Pitavastatin,Ceftobiprole
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Biomedical Advanced Research and Development Authority
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 05, 2025

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Pitavastatin,Ceftobiprole
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Biomedical Advanced Research and Development Authority
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pitavastatin is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 05, 2025

 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
												 
													 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Zevtera
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 500mg
Packaging :
Approval Date : 23/12/2014
Application Number : 65089
Regulatory Info : Allowed
Registration Country : Switzerland

 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
											 
												 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Allowed
Registration Country : Switzerland
Brand Name : Zevtera
Dosage Form : Powder For Concentrate For Solution For Infusion
Dosage Strength : 500mg
Packaging :
Approval Date : 23/12/2014
Application Number : 65089
Regulatory Info : Allowed
Registration Country : Switzerland

 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
13 Aug 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250813478127/en/Innoviva-Specialty-Therapeutics-Antimicrobial-Therapies-ZEVTERA-and-XACDURO-Nominated-for-the-2025-Prix-Galien-USA-Best-Pharmaceutical-Product-Award

20 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250520570730/en/ZEVTERA-ceftobiprole-an-Advanced-Generation-Cephalosporin-Antibiotic-Now-Commercially-Available-in-the-U.S.-to-Treat-Three-Types-of-Bacterial-Infections

16 Apr 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/04/16/3062270/0/en/Basilea-reports-presentation-of-new-data-for-fosmanogepix-isavuconazole-Cresemba-and-ceftobiprole-Zevtera-at-ESCMID-Global-2025.html

28 Jan 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/01/28/3016062/0/en/Strong-sales-growth-for-Cresemba-and-Zevtera-trigger-further-milestone-payments-to-Basilea.html

16 Dec 2024
// BUSINESSWIRE

03 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/03/2874833/0/en/Basilea-reports-presentation-of-new-data-for-ceftobiprole-Zevtera-at-ESCMID-Global-2024.html
Market Place
Reply
07 May 2024
Reply
20 Aug 2022
Reply
15 Dec 2020
Reply
11 Oct 2018
 FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]		
ABOUT THIS PAGE
18
PharmaCompass offers a list of Ceftobiprole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ceftobiprole manufacturer or Ceftobiprole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ceftobiprole manufacturer or Ceftobiprole supplier.
PharmaCompass also assists you with knowing the Ceftobiprole API Price utilized in the formulation of products. Ceftobiprole API Price is not always fixed or binding as the Ceftobiprole Price is obtained through a variety of data sources. The Ceftobiprole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ceftobiprole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ceftobiprole, including repackagers and relabelers. The FDA regulates Ceftobiprole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ceftobiprole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ceftobiprole supplier is an individual or a company that provides Ceftobiprole active pharmaceutical ingredient (API) or Ceftobiprole finished formulations upon request. The Ceftobiprole suppliers may include Ceftobiprole API manufacturers, exporters, distributors and traders.
Ceftobiprole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ceftobiprole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ceftobiprole GMP manufacturer or Ceftobiprole GMP API supplier for your needs.
A Ceftobiprole CoA (Certificate of Analysis) is a formal document that attests to Ceftobiprole's compliance with Ceftobiprole specifications and serves as a tool for batch-level quality control.
Ceftobiprole CoA mostly includes findings from lab analyses of a specific batch. For each Ceftobiprole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ceftobiprole may be tested according to a variety of international standards, such as European Pharmacopoeia (Ceftobiprole EP), Ceftobiprole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ceftobiprole USP).
